中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 36 Issue 3
Mar.  2020
Turn off MathJax
Article Contents

Expression and clinical significance of pseudogene DUXAP8 in liver cancer

DOI: 10.3969/j.issn.1001-5256.2020.03.022
Research funding:

 

  • Received Date: 2019-09-07
  • Published Date: 2020-03-20
  • Objective To investigate the expression,clinical significance,and potential mechanism of action of DUXAP8 in hepatocellular carcinoma. Methods The expression data of liver cancer and related clinical data published up to June 2019 were collected from TCGA database to screen out the differentially expressed long non-coding RNAs( lncRNAs) between liver cancer tissue and adjacent tissue which affected the prognosis of patients. The association of the expression level of DUXAP8 with clinicopathological features and prognosis was analyzed. Gene ontology( GO) and KEGG pathway enrichment analysis was used to investigate the biological functions and biological processes of DUXAP8-related genes. The STRING database and Cytoscape were used to analyze protein-protein interactions and screen out key genes,and then the expression levels of key genes and prognosis were analyzed and a literature search analysis was performed. The Wilcoxon signed-rank test and the Wilcoxon rank-sum test were used to compare the expression of DUXAP8 between liver cancer tissue and adjacent tissue,and the Wilcoxon rank-sum test was used to compare the expression of DUXAP8 between the patients with different clinicopathological features. The Kaplan-Meier method was used to plot survival curves and the log-rank test was used for survival comparison between groups; a Cox regression analysis was used to identify the influencing factors for prognosis. A Pearson correlation analysis was used to analyze DUXAP8-related genes. Results As for the matched and unmatched samples,there was a significant difference in the expression of DUXAP8 between liver cancer tissue and adjacent tissue( P < 0. 001),and the expression of DUXAP8 in liver cancer tissue was significantly higher than that in adjacent tissue. There was a significant difference in the expression of DUXAP8 between the patients with different ages or T stages( P < 0. 05),and the patients with an age of ≥60 years or a T stage of T3 or T4 tended to have higher expression of DUXAP8. The univariate analysis showed that clinical stage,T stage,and expression of DUXAP8 were associated with patients' overall survival( all P <0. 001),and the multivariate Cox regression analysis showed that an advanced clinical stage( hazard ratio [HR]= 1. 648,95% confidence interval [CI]: 1. 330-2. 709,P < 0. 001) and high expression of DUXAP8( HR = 1. 849,95% CI: 1. 262-2. 713,P < 0. 01) were independent risk factors for poor prognosis. The genes involved in the maintenance of tumor cell proliferation and cell cycle were enriched in the samples with high expression of DUXAP8. TOP2 A,KIF2 C,TTK,PLK1,CDCA8,CDC20,NCAPG,BUB1 B,BUB1,and CCNA2 were the Hub genes of DUXAP8-related genes and were mainly involved in the processes such as cell mitosis and cell cycle,and they were the factors for poor prognosis of patients with liver cancer( all P < 0. 05). Conclusion The high expression of DUXAP8 is a risk factor for poor prognosis in patients with liver cancer and DUXAP8 may promote the development and progression of liver cancer by affecting the processes of cell proliferation and cell cycle.

     

  • loading
  • [1] FERLAY J,SOERJOMATARAM I,DIKSHIT R,et al. Cancer incidence and mortality worldwide:Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer,2015,136(5):e359-e386.
    [2] MCGUIRE S. World Cancer Report 2014. Geneva,Switzerland:World Health Organization,International Agency for Research on Cancer,WHO Press,2015[J]. Adv Nutr,2016,7(2):418-419.
    [3] PROUDFOOT N. Pseudogenes[J]. Nature,1980,286(5776):840-841.
    [4] LUCO R F,MISTELI T. More than a splicing code:Integrating the role of RNA,chromatin and non-coding RNA in alternative splicing regulation[J]. Curr Opin Genet Dev,2011,21(4):366-372.
    [5] MARTIANOV I,RAMADASS A,SERRA B A,et al. Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript[J]. Nature,2007,445(7128):666-670.
    [6] XIA T,LIAO Q,JIANG X,et al. Long noncoding RNA associated-competing endogenous RNAs in gastric cancer[J]. Sci Rep,2014,4:6088.
    [7] SAEINASAB M,BAHRAMI AR,GONZALEZ J,et al. SNHG15is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation,invasion and drug resistance in colorectal cancer by interacting with AIF[J]. J Exp Clin Cancer Res,2019,38(1):172.
    [8] XU Z,YANG F,WEI D,et al. Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma[J]. Oncogene,2017,36(14):1965-1977.
    [9] LI Y,LI J,LUO M,et al. Novel long noncoding RNA NMR promotes tumor progression via NSUN2 and BPTF in esophageal squamous cell carcinoma[J]. Cancer Lett,2018,430:57-66.
    [10] JIANG B,HAILONG S,YUAN J,et al. Identification of oncogenic long noncoding RNA SNHG12 and DUXAP8 in human bladder cancer through a comprehensive profiling analysis[J]. Biomed Pharmacother,2018,108:500-507.
    [11] SUN M,NIE F Q,ZANG C,et al. The pseudogene DUXAP8promotes non-small-cell lung cancer cell proliferation and invasion by epigenetically silencing EGR1 and RHOB[J]. Mol Ther,2017,25(3):739-751.
    [12] LIAN Y,YANG J,LIAN Y,et al. DUXAP8,a pseudogene derived lncRNA,promotes growth of pancreatic carcinoma cells by epigenetically silencing CDKN1A and KLF2[J]. Cancer Commun(Lond),2018,38(1):64.
    [13] HUANG T,WANG X,YANG X,et al. Long non-coding RNA DUXAP8 enhances renal cell carcinoma progression via downregulating miR-126[J]. Med Sci Monit,2018,24:7340-7347.
    [14] LI Y,ZHUANG W,HUANG M,et al. Long noncoding RNA DDX11-AS1 epigenetically represses LATS2 by interacting with EZH2 and DNMT1 in hepatocellular carcinoma[J]. Biochem Biophys Res Commun,2019,514(4):1051-1057.
    [15] LIAO HT,HUANG JW,LAN T,et al. Identification of the aberrantly expressed lncRNA in hepatocellular carcinoma:A bioinformatics analysis based on RNA-sequencing[J]. Sci Rep,2018,8(1):5395.
    [16] OUYANG H,ZHANG L,XIE Z,et al. Long noncoding RNA MAFG-AS1 promotes proliferation,migration and invasion of hepatocellular carcinoma cells through downregulation of miR-6852[J]. Exp Ther Med,2019,18(4):2547-2553.
    [17] WANG L,GUO ZY,ZHANG R,et al. Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing for miR-145 in hepatocellular carcinoma[J]. Carcinogenesis,2013,34(8):1773-1781.
    [18] JOHNSSON P,ACKLEY A,VIDARSDOTTIR L,et al. A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells[J]. Nat Struct Mol Biol,2013,20(4):440-446.
    [19] BOOTH HA,HOLLAND PW. Annotation,nomenclature and evolution of four novel homeobox genes expressed in the human germ line[J]. Gene,2007,387(1-2):7-14.
    [20] BREL V,ANNEREAU JP,VISPE S,et al. Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anticancer drug F14512 targeting topoisomerase II[J]. Biochem Pharmacol,2011,82(12):1843-1852.
    [21] NITISS J L. Targeting DNA topoisomerase II in cancer chemotherapy[J]. Nat Rev Cancer,2009,9(5):338-350.
    [22] LIU LM,XIONG DD,LIN P,et al. DNA topoisomerase 1 and2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride[J]. Int J Oncol,2018,53(5):1897-1912.
    [23] PANVICHIAN R,TANTIWETRUEANGDET A,ANGKATHUNYAKUL N,et al. TOP2A amplification and overexpression in hepatocellular carcinoma tissues[J]. Biomed Res Int,2015,2015:381602.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1002) PDF downloads(210) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return